Greco D B, Negreiros E B, Chaieb J A, Ferreira-Lima P, Croce J
Eur J Respir Dis Suppl. 1986;147:323-6.
The efficacy of nedocromil sodium 4 mg or 2 mg q.i.d. in the management of perennial extrinsic asthma was evaluated in a double-blind, placebo-controlled, multicentre trial. Nedocromil sodium, especially at the dose of 4 mg q.i.d., was consistently rated higher than placebo on clinical assessment and diary card measurement. Compared with placebo, there were significant improvements for nedocromil sodium (4 X 4 mg) in asthma severity scores (p less than 0.05 after 1 and 2 weeks of treatment) and clinician's opinion of treatment (p less than 0.001). The results suggest that nedocromil sodium is effective in the maintenance treatment of patients with perennial extrinsic asthma and further studies with longer-term treatment periods are suggested.
在一项双盲、安慰剂对照、多中心试验中，评估了4毫克或2毫克每日四次的奈多罗米钠治疗常年性外源性哮喘的疗效。在临床评估和日记卡测量中，奈多罗米钠，尤其是每日四次4毫克的剂量，始终比安慰剂的评分更高。与安慰剂相比，奈多罗米钠（4×4毫克）在哮喘严重程度评分（治疗1周和2周后p<0.05）和临床医生对治疗的评价（p<0.001）方面有显著改善。结果表明，奈多罗米钠在常年性外源性哮喘患者的维持治疗中有效，并建议进行更长治疗期的进一步研究。
